Stock Analysis
Bio-Techne Corp.TECH
P/E 103.87×· 5Y range 34.68–137.95×· top 15% of history
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsHold22 analystsP/E 103.9× sits at the 85th percentile of its 5.086926762491444-year history.
Cash covers 92% of debt · FY 2026.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Financial Health95
- Quality95
Risks
- Valuation17
- Growth31
Mixed fundamentals at a demanding price.
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
- ✓Altman Z 16.0 — safe-zone balance sheet
- ✓Interest coverage 26.7× — debt well covered
What's happening with TECH
Profile
Strong financial health and earnings quality; valuation and growth lag behind.
How is each axis scored?
- Valuation17/100 · Weak
- P/E vs own history (85th pct)0/25
- FCF yield (2.4%)5/25
- P/S (9.4x)12/25
- EV/EBIT (41.5x)0/25
- Growth31/100 · Weak
- Revenue CAGR (2.4%)6/25
- Net income CAGR (-9.6%)0/25
- EPS CAGR 5Y (-8.6%)0/25
- Fwd implied growth (200.5%)25/25
- Profitability50/100 · Moderate
- ROIC (10.2%)12/25
- ROE (5.2%)5/25
- Net margin (9.0%)13/25
- Operating margin (22.7%)20/25
- Financial Health95/100 · Strong
- Altman Z (15.97)25/25
- Current ratio (4.55)25/25
- Interest coverage (26.7x)25/25
- Net cash / debt (D/A 1%)20/25
- Quality95/100 · Strong
- Piotroski F (8/9)25/25
- Beneish M (-2.46)20/25
- FCF conversion (246%)25/25
- Margin stability (σ 4.2%)25/25
- Moat68/100 · Moderate
- ROIC >12% years (1/10 yrs)0/25
- Median gross margin (66.5%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 6.0%)18/25
Risk Flags
- ⚠P/E 103.9× at top 15% of 5-year history
About Bio-Techne Corp.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. Show more
It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Headquarters: MINNEAPOLIS, MN · Employees: 3,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
17EP/E (TTM)103.9xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 34.7x–137.9x · 85th pct
P/FCF43.2xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.4%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.0%–4.0% · 69th pct
P/S (TTM)9.40xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 5.6x–25.7x · 37th pct
EV/EBIT41.5xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 28.4x–105.5x · 17th pct
EV/Sales9.3xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E34.6xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio5.40xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio9.81D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.44%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio27.4%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
50CROIC10.2%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE5.2%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA7.1%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin9.0%C
Grade C: AverageNet Income / Revenue
Operating Margin22.7%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin65.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin22.3%A
Grade A: HighFCF / Revenue
True FCF Margin18.9%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
31DRevenue CAGR2.4%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-9.6%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-8.6%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth200.5%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-3.2%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income37.1%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue3.4%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
95A+Altman Z-Score15.97A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.55xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.35xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage26.7xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment0.1yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT0.1xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.14xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.92xC
Grade C: PartialCash covers how much of total debt. >1 = could repay all debt from cash
Quality
95A+Piotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.46A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion246.1%A
Grade A: StrongFCF / Net Income
Margin Stability4.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.1%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.48xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
BAUMGARTNER ROBERT V Filed | BAUMGARTNER ROBERT V | Option exercise | -15940 | |
BAUMGARTNER ROBERT V Filed | BAUMGARTNER ROBERT V | Tax withholding | -5559 | |
BAUMGARTNER ROBERT V Filed | BAUMGARTNER ROBERT V | Option exercise | +15.9K | |
Crouse Steven C. Filed | Crouse Steven C. | Grant / award | +14.1K | |
Crouse Steven C. Filed | Crouse Steven C. | Grant / award | +8.7K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Herr Amy E. Filed | Herr Amy E. | Grant / award | +1.4K | |
Bohnen Shane Filed | Bohnen Shane | Grant / award | +18.4K | |
Bohnen Shane Filed | Bohnen Shane | Grant / award | +11.3K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
68BROIC >12% Years1/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)66.5%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor6.0%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$0.70
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$1.70
Cash & short-term investments per share (Finnhub)
Book Value / Share$13.51
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$289.09M
Total debt obligations (short + long term)
Cash & Equiv.$265.48M
Cash and short-term investments
Net Debt$23.61M
Total Debt minus Cash. Negative = Net Cash position
Total Equity$2.11B
Shareholders' equity (book value)
Asset / Liability5.41xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$11.38B
Current Market Capitalization
Beta1.29C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Bio-Techne Corp. (TECH)
Bio-Techne Corp. meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 15.97 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.46 suggests a low likelihood of earnings manipulation.
- Bio-Techne Corp. converts about 22% of revenue into free cash flow — strong cash generation.
- Takes ~0.1 years to repay net debt from free cash flow.
- At a valuation score of 17/100, TECH trades at a premium to its historical multiples (P/E 103.9).
See how TECH ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TECH moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 5 | Regular | 72.58 | +0.24% | 2.02 |
| Oct 5 | After-hours | 72.58 | +0.25% | 2.07 |
Frequently Asked Questions about TECH
What is the current Bio-Techne Corp. (TECH) stock price?
TECH is trading at $72.57 at the last market close, up 0.07% on the session. PreMarketPrice tracks TECH pre-market, intraday and after-hours prices.
Is TECH stock a buy right now?
PreMarketPrice's quantitative model rates Bio-Techne Corp.'s financial health at 95/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TECH stock overvalued?
Bio-Techne Corp. trades at a trailing P/E of 103.9 and our valuation score rates it 17/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Bio-Techne Corp. report earnings?
No confirmed earnings date is currently scheduled for TECH. The Earnings section lists recent reports and updates as dates are announced.
What sector does Bio-Techne Corp. operate in?
Bio-Techne Corp. operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Bio-Techne Corp. do?
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets.
About Bio-Techne Corp. (TECH) Stock
Bio-Techne Corp. (TECH) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Bio-Techne Corp. is trading at $72.57, up 0.07% on the day with a market capitalization of $11.4 billion. The financial health score for TECH is 95/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TECH stock.
TECH Stock Analysis & Key Metrics
On PreMarketPrice, you can track Bio-Techne Corp. (TECH) across multiple dimensions:
- Pre-market price & movement: Real-time TECH stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TECH with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Bio-Techne Corp. across multiple reporting periods.
- Financial health score: A composite score of 95/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TECH.
- Sector peers: Compare TECH against 5 other healthcare stocks on key financial metrics.
Is TECH a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Bio-Techne Corp. (TECH) as an investment. The financial health score of 95/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Bio-Techne Corp. (TECH) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.